• AstraZeneca will acquire Amolyt Pharma for up to $1.05 billion in total consideration
• The transaction is expected to close in the third quarter of 2024

Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrine and related diseases, today announced it has entered into a definitive agreement for AstraZeneca to acquire Amolyt Pharma at a purchase price of $800 million upfront and a potential milestone payment of $250 million. Alexion, AstraZeneca Rare Disease is looking forward to welcoming talent from Amolyt Pharma

“We are proud of the remarkable achievements of our team in building and developing a portfolio of therapeutic peptides with the potential to address significant unmet needs for rare endocrine and related diseases, having advanced eneboparatide to Phase 3 for hypoparathyroidism and created an early-stage pipeline in less than 5 years. We are grateful to the investigators, patients, and patient associations who have supported us to reach these goals,” said Thierry Abribat, Ph.D., Founder and Chief Executive Officer of Amolyt Pharma. “We are looking forward to the development of our portfolio as part of Alexion, AstraZeneca Rare Disease, an organization with proven expertise and a successful track-record in bringing innovative therapies to patients with rare diseases globally.”

Raphaël Wisniewski, partner at Andera Partners, commented “we are proud to have accompanied Amolyt since 2021. This was the first investment of the BioDiscovery 6 fund in France. The company led by Thierry Abribat and an exceptional management team has developed innovative therapies for rare endocrine diseases. This acquisition by AstraZeneca exemplifies the dynamism of biotech in France and Europe. We congratulate the management and employees of Amolyt who are dedicated to the development and the success of the company.“

Amolyt’s clinical pipeline includes differentiated therapeutic peptides for the treatment of underserved rare endocrine disease. Eneboparatide (AZP-3601) is an investigational daily subcutaneous injectable parathyroid hormone receptor 1 (PTHR1) agonist for the treatment of hypoparathyroidism, that is currently in Phase 3. AZP-3813 is a peptide growth hormone receptor antagonist for the potential treatment of acromegaly that is in Phase 1.

Share on :

More news